Competitor Analysis: Targeted Therapy of Diabetes
Product description
The present Competitive Intelligence Report about Targeted Therapy of Diabetes provides a competitor evaluation in the field of novel molecules being developed for treatment of type 1 and 2 diabetes as of April 2011. Major pharmacologic approaches include insulin, PPAR agonists, DPP-IV inhibitors, GLP-1 analogs and SGLT inhibitors. Furthermore, emerging approaches for diabetes therapy are reported including glucokinase activators and 11beta-HSD1 inhibitors. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. Competitor projects are listed in a tabular format providing information on:
Insulin
PPAR Agonists
Dipeptidyl peptidase-IV (DPP-IV) Inhibitors
Sodium-Dependent Glucose Co-Transporter 2 (SGLT-2) Inhibitors
11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
Glucokinase Activators (GKA)
Other Emerging Diabetes Drugs
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The present Competitive Intelligence Report about Targeted Therapy of Diabetes provides a competitor evaluation in the field of novel molecules being developed for treatment of type 1 and 2 diabetes as of April 2011. Major pharmacologic approaches include insulin, PPAR agonists, DPP-IV inhibitors, GLP-1 analogs and SGLT inhibitors. Furthermore, emerging approaches for diabetes therapy are reported including glucokinase activators and 11beta-HSD1 inhibitors. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in research and development of novel molecules for treatment of type 1 and 2 diabetes. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Insulin
- Rec Human Insulin for Injection (2nd Generation)
- Biosimilar Rec Human Insulin for Injection (2nd Generation) in
- Regulated Markets
- Rhu Insulin (2nd Generation) in Off-Patent Countries: China
- Rhu Insulin (2nd Generation) in Off-Patent Countries: Russia
- Rhu Insulin (2nd Generation) in Off-Patent Countries: India
- Rhu Insulin (2nd Generation) in Off-Patent Countries: Others
- Modern Insulin Analogs (3rd Generation) for Injection
- Modern Insulin Analogs (3rd Generation) in Less-Regulated Markets
- Tailored and Novel Insulin Analogs (4th Generation) for
- Injection
- Human Insulin with Drug Delivery for Injection
- Other Long-Acting Insulin for Injection
- Transgenic Human Insulin for Injection
- Insulin/GLP-1 Combination Products
- Inhaled Insulin
- Oral Insulin
- Transdermal Insulin
- Others
PPAR Agonists
- PPAR alpha Agonists
- PPAR gamma Agonists / Insulin Sensitizer
- PPAR alpha and gamma Agonists
- PPAR delta Agonists
- PPAR delta and gamma Agonists
- PPAR alpha and delta Agonists
- PPAR pan Agonists (alpha, gamma and delta)
- Unspecified PPAR Agonists
Dipeptidyl peptidase-IV (DPP-IV) Inhibitors
- GLP-1 Receptor Agonists
- GLP-1 Analogs with Daily SC Injections
- GLP-1 Analogs with Once Weekly SC Injections
- GLP-1 Analogs with Bi-Weekly or Monthly SC Injections
- Other GLP-1 Analogs for SC Injections
- GLP-1 Analogs in Drug Delivery Formulations/Devices for
- Parenteral Administration
- GLP-1 Analogs in Drug Delivery Formulations for Oral
- Administration
- Oral Small Molecule GLP-1 Receptor Agonists
- Dual Target GLP-1 Receptor Agonists / Combination Products
- GLP-1 Analogs in Other, Non-Diabetes Indications
Sodium-Dependent Glucose Co-Transporter 2 (SGLT-2) Inhibitors
11beta-Hydroxysteroid Dehydrogenase Type 1 (11beta-HSD1) Inhibitors
Glucokinase Activators (GKA)
Other Emerging Diabetes Drugs
- Adenosine Monophosphate Activated Protein Kinase (AMPK) Agonists
- Sirtuin (SIRT) Activators
- Protein tyrosine Phosphatase-1B (PTP-1B) Inhibitors
- Glucagon Receptor (GCGR) Antagonists
- Glucocorticoid Receptor (GCGR) Antagonists
- Novel Insulin Sensitizers
- G-Protein Coupled Receptor 119 (GPR119) Agonists
- Other Drugs Augmenting GLP-1 Secretion: GPR40, GPR120 & TGR5 Agonists
- Other Glucometabolic Approaches
- Acyl-CoA:Diacylglycerol Acyltransferase1 (DGAT1) Inhibitors
- Other Metabolic Approaches
- FGF-21-Receptor Agonists
- Anti-Inflammatory Approaches
- Induction of Immune Tolerance
- Pancreatic Beta Cell Protection & Regeneration
- Pancreatic Islet Cell Transplantation
- Various Antidiabetic Approaches
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
